Remove Licensing Remove Marketing Remove Packaging
article thumbnail

Using Rapid Development Environment in AEM as a Cloud Service

Perficient: Drug Development

Depending on the size of the team and anticipated activity within a program, additional RDEs can also be provisioned, however, this may come at an additional licensing cost from Adobe. In this simple example, a content package is deployed with the aio aem:rde :install command.

Packaging 105
article thumbnail

Royalty Pharma and Revolution Medicines Sign Funding Deals Worth Up to $2 Billion

The Pharma Data

securing a funding package of up to $2 billion. This aligns both parties’ interests toward long-term success in the market. With a total package of up to $2 billion, the agreement between Royalty Pharma and Revolution Medicines underscores growing investor confidence in the viability and future of targeted RAS inhibition.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The rise of GLP-1 drugs: Transforming weight loss treatment

BioPharma Drive: Drug Pricing

The black and gray market risks Ben warned about the proliferation of counterfeit GLP-1 drugs in unregulated markets, posing significant dangers to patients who might unknowingly use ineffective or harmful products. The balance is complex, as obesity carries its own serious health risks.

Treatment 130
article thumbnail

Nine Key Takeaways from Dreamforce 2023

Perficient: Drug Development

Increased Capabilities for Marketing Cloud and Commerce Cloud Salesforce introduced 26 generative AI capabilities between Marketing Cloud and Commerce Cloud, 14 of which are in GA now, with an additional 14 to arrive by the end of 2024.

article thumbnail

Article EMA Thank You New MHRA Windsor Framework documents guide post-Brexit flow of medicines for U.K., Great Britain, and the E.U.

Agency IQ

This past week, the MHRA provided guidance on labeling of medicines destined for Northern Ireland, with provisions to ensure that medicines only move into Northern Ireland market and don’t re-enter E.U. The European centralized marketing authorization procedure is no longer a valid medicines approval pathway for the U.K. member states.

article thumbnail

Do You Have a Combination Product, and Is It Drug-led or Device-led? Early Regulatory Insights

The Premier Consulting Blog

With the promise of simplified and improved treatments, the $118 billion combination-product market is projected to increase at a compound annual growth rate (CAGR) of 8.8%. e) reveals more detail — and gray areas: Two or more regulated components, in one package (e.g., The drug product is packaged and shipped as a solid powder.

article thumbnail

Making Sense of Sitecore’s Headless Options

Perficient: Drug Development

Usually, Sitecore Headless Services can be implemented using the current licensing model, providing a seamless transition for existing Sitecore users, however we have seen clients on perpetual licenses need to negotiate with Sitecore to add this capability to their license. XM Cloud is where Sitecore is innovating.